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Abstract Psychiatric adverse drug reactions (ADRs)
have been reported with statin use, but the literature
regarding statin-associated mood/behavioral changes
remains limited. We sought to elicit information germane
to natural history and characteristics of central nervous
system/behavioral changes in apparent connection with
statin and/or cholesterol-lowering drug use, and delineate
mechanisms that may bear on an association. Participants
(and/or proxies) self-referred with behavioral and/or mood
changes in apparent association with statins completed a
survey eliciting cholesterol-lowering drug history, charac-
ter and impact of behavioral/mood effect, time-course of
onset and recovery in relation to drug use/modification, co-
occurrence of recognized statin-associated ADRs, and
factors relevant to ADR causality determination. Naranjo
presumptive ADR causality criteria were assessed. Partic-
ipants (n = 12) reported mood/behavior change that com-
menced following statin initiation and persisted or
progressed with continued use. Reported problems inclu-
ded violent ideation, irritability, depression, and suicide.
Problems resolved with drug discontinuation and recurred
with rechallenge where attempted. Eight met presumptive
criteria for ‘‘probable’’ or ‘‘definite’’ causality; others had
additional factors not considered in Naranjo criteria that
bear on casual likelihood. (1) Simvastatin 80 mg was
followed in 5 days by irritability/depression culminating in
suicide in a man in his 40s (Naranjo criteria: possible
causality). (2) Simvastatin 10 mg was followed within
2 weeks by depression in a woman in her 50s (probable
causality). (3) Atorvastatin 20 mg was followed in *1
month by depression and irritability/aggression in a male in
his 50s (probable causality). (4) Atorvastatin 10 mg was
followed in several months by aggression/irritability and
depression culminating in suicide in a man in his 40s
(possible causality). (5) Fenofibrate ? rosuvastatin (un-
known dose), later combined with atorvastatin were fol-
lowed in 1 month by aggression/irritability in a male in his
30s (probable causality). (6) Lovastatin (unknown dose and
time-course to reaction) was followed by depression,
dyscontrol of bipolar disorder, and suicide attempts in a
male in his 40s (possible causality). (7) Atorvastatin 20 mg
was followed within 2 weeks by cognitive compromise,
and nightmares, depression, and anxiety culminating in
suicide in a man in his teens (definite causality). (8) Sim-
vastatin 10 mg was followed (time-course not recalled) by
depression, aggression/irritability culminating in suicide in
a man in his 60s (possible causality). (9) Simvastatin
20 mg then atorvastatin 10 mg were followed (time-course
not provided) by irritability/aggression in a man in his 60s
(definite causality). (10) Atorvastatin 10 then 20 then
40 mg were followed shortly after the dose increase by
violent ideation and anxiety in a man in his 30s (probable
causality). (11) Atorvastatin 20 mg and then simvastatin
20 mg were followed in 2 weeks by aggression/irritability
in a man in his 50s (definite causality). (12) Lovastatin,
rosuvastatin, atorvastatin, and simvastatin at varying doses
were followed as quickly as 1 day by aggression, irri-
tability, and violent ideation in a man in his 40s (definite
causality). Most had risk factors for statin ADRs, and co-
occurrence of other, recognized statin ADRs. ADRs had
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implications for marriages, careers, and safety of self and
others. These observations support the potential for adverse
mood and behavioral change in some individuals with
statin use, extend the limited literature on such effects, and
provide impetus for further investigation into these pre-
sumptive ADRs. Potential mechanisms are reviewed,
including hypothesized mechanisms related to oxidative
stress and bioenergetics.
Key Points
Psychiatric adverse effects, altering mood,
personality, and behavior, sometimes arise in
patients receiving statins.
Statin psychiatric effects can include irritability/
aggression, anxiety or depressed mood, violent
ideation, sleep problems including nightmares, and
possibly suicide attempt and completion.
Introduction
Most adverse drug reaction (ADR) reporting focuses on
non-behavioral health risks to the medication-taking indi-
vidual; however, attention is increasingly given to drug-
induced behavioral and mood changes that may affect self
or others. Drugs and medications with behavioral concerns
include alcohol (best recognized) [1], but also varenicline
[2–4], loratadine [5], mefloquine [6], tramadol [7, 8], iso-
tretinoin [9], tricyclics [10], benzodiazepines [11, 12], and
selective serotonin reuptake inhibitors (SSRIs) [13–16],
among others [17]. Emerging evidence suggests such
problems may occasionally arise with cholesterol-lowering
drugs [18–20]. These drugs are widely prescribed and most
prominently include statins (3-hydroxy-3-methylglutaryl
coenzyme-A reductase inhibitors), which held the place of
best-selling class of prescription drugs in the world and
include the best-selling prescription drug in history [21–
24].
Neuropsychiatric ADRs of statins, including suicide and
aggression, have been reported in pharmacovigilance
databases [20, 25] and in adverse event reports and series
[18, 19, 26]. Moreover, adverse behaviors have been
reported in settings of low cholesterol [27–29]; and of
lower omega-3 fatty acid levels (the omega-3 to omega-6
ratio is reportedly reduced with statins) [30–32]. Both
naturally low cholesterol and randomized assignment to
cholesterol reduction in the pre-statin era have been
reported to be linked to increased violent deaths [28, 33,
34], though statin randomization has not [35]. Recent
randomized controlled trial (RCT) evidence indicating that
statins can have bidirectional effects on aggression may be
germane here: different mediating factors, including
increased sleep problems and perhaps reduced testosterone,
appear to drive effects in differing directions, and bidi-
rectional effects on oxidative stress may also be speculated
to do so. Nonetheless, the literature relating mood and
behavioral changes to cholesterol-lowering drugs, and
depicting the character and potential implications of
adverse psychiatric effects with statins, remains relatively
sparse [18, 20, 25, 36, 37]. Here we present 12 cases of
mood and behavioral change apparently associated with
lipid-lowering agents.
Methods
A total of 12 subjects and/or their family members (if the
subject was deceased) who reportedly experienced mood
and behavioral changes while receiving one or more statin,
as identified by the subject and/or by family members,
contacted our study group and provided survey informa-
tion. Written informed consent was obtained from each
participant (or proxy for deceased subjects) for inclusion of
their case in this case series. These 12 represent a conve-
nience sample, chosen because the neuropsychiatric prob-
lem was the primary complaint, because the nature or
severity appeared to warrant representation in the litera-
ture, because the participant or proxy was amenable to
inclusion (with proper de-identification), and because the
aggregate number, 12, was small enough to allow inclusion
of some individual detail, yet sufficient to illustrate a suite
of potential issues.
Elicited information included demographic characteris-
tics, drug(s) used (statin and concomitant medications),
dose(s), time-course of mood and behavior change relative
to drug use (onset, duration, recovery), character of
symptoms, and open-ended narrative of the impact of
behavior, mood, and/or personality changes. We inquired
whether a modification to the treatment regimen occur-
red—such as changes in dose, drug discontinuation, and
drug rechallenge—and the impact on symptoms. Recog-
nized risk factors for statin ADRs, and development of
other recognized statin ADRs, were also elicited. Infor-
mation for each case is presented in tabular form.
Cases were assessed for adherence to presumptive
causality criteria using the published Naranjo drug ADR
causality classification. This employs a point system of
positive and negative causality points to estimate the
probability of an ADR, with a score C9 deemed to indicate
‘‘definite’’ ADR causality, 5–8 ‘‘probable’’, 1–4 ‘‘possi-
ble’’, and B0 ‘‘doubtful’’ [38]. For all participants, adverse
event causality was at least ‘‘possible’’, since psychiatric
1 Page 2 of 13 S. Cham et al.
and behavioral reactions to statins or cholesterol reduction
bear biological plausibility and prior reports. ‘‘Probable’’
causality was limited to those who experienced occurrence
following drug initiation, had the drug discontinued, and
improved following drug discontinuation. ‘‘Definite’’
causality assignments were limited to those who, in addi-
tion to recovery with discontinuation, were rechallenged
with the drug, and experienced symptom recurrence.
Results
Information on drug, drug dose, reported mood and
behavioral effect, factors supporting a causal connection,
other statin symptoms, family history of psychiatric prob-
lems associated with statin use, and presence of risk factors
for statin adverse effects are listed in Table 1. Cases
commonly involved more than one psychiatric element
(Table 2). An expanded description of each case is pro-
vided (Table 3). Marked change in mood and/or behavior
was commonly noted, in some instances leading to tragic
consequences. In some cases, proximal mood or behavioral
changes arising with cholesterol-lowering agents led to the
addition of psychiatric medications, and a role for these
psychotropic medications in behavioral sequelae cannot be
excluded. Behavioral/mood findings often accompanied
muscle, cognitive, or other better recognized statin adverse
effects [39–41]. Some participants had family members
who also had experienced psychiatric adverse effects
attributed to statins. Several participants exhibited com-
pelling on-off-on reproducibility of findings.
Based on Naranjo presumptive criteria for ADR
causality, eight cases qualified as bearing a ‘‘probable’’ or
‘‘definite’’ causality designation. The four cases designated
‘‘possible’’ are included because of factors not considered
in Naranjo criteria that bear on likelihood of a causal
connection. (As was said for a drug bearing a similar
spectrum of behavioral adverse behaviors, ‘‘the clear
temporal relationship, lack of prior history of this behavior,
and unusual nature of these events strengthens the accu-
mulating scientific evidence’’ [2]). Each patient exhibited
persistent absence of the symptom prior to administration
of the statin, followed by persistent presence while
receiving the statin (days to years). One possible exception
was a man with bipolar disorder; however, he had mani-
fested years of stability and good control since initiation of
lithium until statin initiation, which resulted in loss of
psychiatric stability persisting for the years he was
receiving statins until his death. Prospects for a causal
connection were buttressed by an adverse behavioral
change while receiving statins in a first-degree relative who
also experienced dechallenge–rechallenge support (family
history and genetics are risk factors for statin problems)
[46–52]. A total of 75 % of cases were accompanied by
other symptoms with a confirmed relation to statin use,
including muscle symptoms [41, 53–60], cognitive prob-
lems [40, 61–63], and dermatologic reactions [39]. Addi-
tionally, 50 % of cases had factors previously shown to be
linked to an elevated risk of statin ADRs, such as thyroid
conditions [39].
Discussion
Summary
Behavioral and psychiatric changes in the cases presented
range from violent nightmares to aggression, mood/per-
sonality change, violent or homicidal ideation (in some
instances culminating in suicide), each in apparent asso-
ciation with statin use. The temporal association between
the drug initiation and mood and behavior change, and
again between drug discontinuation and resolution of
symptoms where this occurred, suggests a causal connec-
tion in a number of these cases. Notable mood and
behavioral changes for all patients or introduction of seri-
ous psychiatric events began after drug initiation. The
latency profile is consistent with that for other statin ADRs
that share common mechanisms [40, 41], and bear RCT
support [39, 59, 61, 62]. Symptoms persisted or progressed
with continued use in all cases. Those able to discontinue
the drug experienced resolution of symptoms. For those in
whom rechallenge was possible, symptoms recurred. The
presence of ADRs and risk factors with a confirmed rela-
tion to statin ADRs is consistent with common patho-
physiological factors, hypothesized to underlie many statin
adverse effects, extending to behavioral effects [39]. (12
cases are included; for those interested in knowledge of
other cases of this kind, a 13th case, involving a physician
with behavioral changes while receiving statins and leading
to professional review, is planned for inclusion in a sepa-
rate manuscript on statin adverse effects in physicians).
Explanation of Findings; Comparison/Contrast
with Other Findings in Literature
Though a relation of statins to instances of behavior
alteration may seem counterintuitive, it fits with a body of
existing literature. Observationally, lower cholesterol has
been linked to greater violence (including aggression,
suicide, homicide, violence) in many studies, including
prospective longitudinal studies [28, 29, 64, 65]. Behav-
ioral consequences of lipid-lowering medications have
been reported for non-statin treatments, including fibrates
[20] (implicated in case 5), with support extending to meta-
analyses of RCTs showing significantly increased violent
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death [28, 33, 34]. RCT meta-analysis in the statin era did
not support an increase in violent death on average (indeed
the point estimate was lower, though not significantly)
[35]. RCT patient selection may be one factor: excess
violent deaths on pre-statin lipid drugs were preferentially
evident in those with risk factors for violence—e.g.,
alcohol, psychiatric history, and non-compliance [66]. Of
note, there was no evidence of more patients with these
characteristics in the cholesterol-lowering group, but the
excess of events emphasized these patients. Psychiatric
histories, alcohol/substance use, and low conscientiousness
are risk factors for lower compliance, so may lead to
exclusion with compliance run-ins, but are also risk factors
for adverse behaviors, so vulnerable individuals might be
preferentially excluded [67]. Relative exclusion may affect
detection of risk in two ways. First, the same fractional
(relative) risk change will lead to a greater number
affected, and more power to show a change, in those at
higher risk (a doubling of nothing is still nothing) [68].
Second, the fractional risk change itself may be greater in
a behaviorally vulnerable subset (effect modification):
illustrating this point, the odds ratios risk of psychiatric
events with mefloquine use was reported to be 3.8 among
those without a psychiatric history, versus apparently
double that (8.0) in those with a psychiatric history [6].
Other factors may also explain this. Randomized trial
evidence examining statin effects on aggression provides
potential insights: statins (vs. placebo) promoted both
average significant increases and reduction in aggression,
in different groups [69]. Typical effects in men (particu-
larly in men who were both younger and less aggressive at
baseline) were toward reduced aggression [69], with older
age and female sex shifting the distribution. Simvastatin
has been shown to both significantly lower testosterone
[70] and worsen sleep problems on average [43]. (It may
also promote sleep apnea in some [71]). For men receiving
simvastatin, the magnitude of each of these effects sig-
nificantly predicted the change in aggression, in opposite
directions [69]. Sleep problems and sleep apnea are else-
where linked to irritability [72–74], as well as aggression
and violence [75]. Lower testosterone in some settings is
linked to lower aggression and violence [76, 77].
Other mechanisms may be theorized. Low central
serotonin has been linked to low cholesterol and to
aggression [28, 78, 79]. However, whole blood serotonin
(which correlates inversely to central serotonin) did not
predict aggression in mediation analysis within a ran-
domized trial [69]. We also hypothesize that effects on
aggression, and perhaps mood problems on statins, may be
linked to oxidative stress [80] and inter-related mito-
chondrial dysfunction (which has been linked to temper
disorders) [81]. The explanation accords with our finding
that behavioral adverse effects commonly co-occur withT
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better known statin adverse effects, with the documented
relation of better known statin adverse effects to oxidative
stress and mitochondrial dysfunction [39], and with the
documented connection of mitochondrial dysfunction to a
range of psychiatric problems [82–87].
Other hypothetical mechanisms of potential relevance,
such as the role of cholesterol in synapse formation or
membrane function, and myelin production have been
reviewed elsewhere [40, 88], but in contrast to mechanisms
cited above, triangulating evidence for a role is currently
lacking.
The explanation accords with our finding that behavioral
adverse effects commonly co-occur with better known
statin adverse effects, for which a relation to oxidative
stress and mitochondrial dysfunction has been elucidated
[39]. Mitochondrial dysfunction has a documented con-
nection to a range of psychiatric problems [82–87], and
may also contribute to behavioral change with statin-in-
duced oxidative damage.
More lipophilic statins have better brain penetration [89,
90], though all statins have some ability to cross the blood–
brain barrier [91]. Whether this is important for central
effects of the kinds described is unknown, since peripheral
effects can have central consequences—and since prooxi-
dant effects of statins, which are linked to the occurrence of
statin adverse effects [92], also raise blood–brain barrier
penetrability [93, 94]. Each of the patients in our report
experienced problems while receiving at least one of sim-
vastatin, atorvastatin, or lovastatin, which are lipophilic
statins. However, most involved atorvastatin and simvas-
tatin, which have also historically been the most frequently
prescribed statins. This, and the lack of a defined base
population in which statin prescribing rates are known,
obviates our ability to comment on whether lipophilicity is
relevant to these effects.
Limitations
This study has the limitations inherent to all case series:
data are observational, which constrains causal inference.
However, a profound change in state while receiving a
drug, particularly with dechallenge–rechallenge support,
strengthens the case for causality. There is no defined base
population or control group, precluding calculation of
rates and risk ratios, and occurrence of adverse neu-
ropsychiatric effects in these cases, even if presumed
causal, has no inherent implications for usual effects of
statins on the outcomes reported—nor do usual effects
have necessary implications to individual ones. Rather,
this case series underscores that statins may in specific
individuals promote adverse behavioral, mood, and per-
sonality changes, irrespective of whether behavioral (or
mood) effects are on average favorable, adverse, or neu-
tral. Even reporting rates relative to other ADRs may be a
challenge to gauge meaningfully for neuropsychiatric
problems, because these may be particularly sensitive,
and may go unreported. In an analysis of emails
abstracting statin ADRs mentioned spontaneously, mood
or personality problems were spontaneously related as
part of the ADR complex in a minority, but in a survey
directly asking about each of a list of symptoms the
participant attributed to statins, among those self-selected
for having at least one such symptom, a majority cited a
neuropsychiatric effect. (However, in the latter, there is
Table 2 Psychiatric elements present in more than one case
Case Short temper/
aggression/
irritability
Violent ideation Completed
suicide
Depression Joyless/
hopeless
Reduced
socializing/
activity
Anxiety Impatience
1 x x x x x x x
2 x x
3 x x x
4 x x x x
5 x
6 x
7 x x x
8 x x x x x
9 x
10 x x
11 x
12 x x
Total 8 2 4 7 4 2 3 2
Manifestations reported by only one participant include paranoia, detachment, suicidal ideation, loss of appetite, nightmares, attention/con-
centration problems, increased emotional response, mania, and dyscontrol of bipolar disorder
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Table 3 Description of twelve mood/behavior cases associated with cholesterol-lowering drug use
Case Case history
1 Case 1, a professionala male in his 40s with a history of psoriasis and two negative stress SPECT tests, with no personal or family history of
psychiatric illness, was placed on simvastatin 80 mg for hyperlipidemia (TC 262 mg/dL, TRG 123 mg/dL, HDL 35 mg/dL, and LDL 202 mg/
dL). No concomitant medications were being taken
By 5 days after initiation of high-dose simvastatin (80 mg: a dose for which there is now a US FDA advisory [42]), his wife noted development of
marked, uncharacteristic behavior changes, including a ‘‘darker change in affect’’, with relative loss of his previously bright personality and sense
of humor. His wife describes him as having been an avid cook who also enjoyed substantive conversation; he lost interest in both following statin
initiation. These altered personality and behavior characteristics progressed over the ensuing months, with manifestations including irritability,
detachment, attention problems, joylessness, anxiety, fatigue, impatience, insomnia, and reduced social interest/activities, accompanied by non-
psychiatric symptoms of altered temperature regulation (feeling cold while others felt hot) and ‘‘muddled thinking’’, [39]). As a former editor of
the Law Review at his university’s Law School, he was perceived to have brilliant career prospects. He was successful in a demanding job, but the
marked cognitive changes seriously affected his work performance, engendering significant work-related stress. Approximately 2 months after
statin initiation, modestly elevated ALT levels were noted (64 and 72 units/L). He was diagnosed with non-alcoholic fatty liver disease. 6 months
after statin initiation, he sought a psychiatrist, with the chief complaint of depression; his mental status was evaluated and a diagnosis of
adjustment disorder and depressed mood was made
He had no familial or previous personal history of psychiatric illness. Risk factors for psychiatric illness included occupational stress; however, this
appeared to be substantially a consequence of his newly impaired cognition. Cholesterol levels after 7 months of treatment were TC 172 mg/dL,
TRG 158 mg/dL, HDL 38 mg/dL, and LDL 102 mg/dL. Over the next 3 months, he had bi-monthly visits with a social worker that focused on
job-related stress, while concurrently family members continued to note a change in personality and decreased sociability. 1 month later, a rash
unrelated to his psoriasis appeared on both arms. 2 days after the rash, he was prescribed temazepam 15–30 mg by a psychiatrist for sleep
problems that included insomnia, nausea, and tightness in the chest, which had surfaced in the previous months. During the psychiatric
medication evaluation, the psychiatrist noted ‘‘his thought processes are well-organized and expressed in a concise linear fashion… the patient
does not exhibit paranoid or grandiose delusional thinking … he is not a danger to himself or others … his insight and judgment are overall
intact’’
7 days later, 9 months after initiating statins, he committed what family members describe as a ‘‘completely unexpected’’ suicide with a gunshot
wound to the head and self-inflicted wounds to the wrists and neck. Toxicology reports reveal no alcohol or commonly abused drugs in his
system at the time of death
Factors meriting note: no familial history of psychiatric illness, no history of alcohol abuse. Fatty liver is tied to metabolic syndrome factors, which
are strong risk factors for statin adverse effects and may sometimes be consequences of them [39]. Sleep problems, noted here, are a reported
adverse effect of simvastatin [43], as are GI problems and skin rashes, which were also noted while receiving statins [39]. Benzodiazepines, given
due to sleep problems arising on statins, may have been a contributory or mediating factor. (Hereafter, concurrent AEs consistent with statin
effects are listed only in Table 1). In our AE reporting system, temperature dysregulation is also a commonly reported statin adverse effect
2 Case 2 is a female in her 50s with a history of autoimmune thyroid disorder, taking 100 lg of levothyroxine for treatment. She was prescribed
10 mg/day of simvastatin for treatment of borderline hyperlipidemia (TC 205 mg/dL)
Within 2 weeks of statin initiation, she noted extreme muscle cramps that would wake her during the night, as well as other symptoms including
muscle weakness (e.g., decreased walking ability), muscle pain (in the shoulders), and shortness of breath, and she began taking ibuprofen to
manage the pain. This was followed by marked change in mood/emergence of depression. Manifestations of this change included wanting to
leave her husband (despite over 20 years of a happy marriage), joylessness (felt that there was a ‘‘veil’’ between her and others, and the inability
to feel happy at her daughter’s wedding), desire for isolation, wanting to quit her job, and loss of appetite and energy. Approximately 1–2 months
after statin initiation, cholesterol levels were taken: TC 180 mg/dL, TRG 50 mg/dL, HDL 52 mg/dL, and LDL 118 mg/dL
After 3 months of statin treatment with adverse mood/personality change, she discontinued the statin (primarily due to the depression) and reported
her symptoms to her physician
Mood improvement was evident by 1 month after discontinuation of lipid therapy, and full recovery had occurred by 3 months. A longer time,
approximately 1 year after statin discontinuation, was required for full resolution of muscle symptoms. 16 months after statin discontinuation TC
is 209 mg/dL
Factors meriting note: no familial history of psychiatric illness, no history of alcohol abuse
3 Case 3, a male professionala in his late 50s, began atorvastatin treatment at 20 mg/day for hyperlipidemia and CAD prevention (TC 215 mg/dL and
mildly elevated LDL), which he reduced to 10 mg/day because he ‘‘did not feel well’’ on 20 mg. On the 10-mg/day dose, his TC was 170 mg/dL
and LDL was approximately 90 mg/dL
Approximately 1 month after initiating atorvastatin, his wife noted new adverse mood and personality changes: increased irritability, periods of
mild depression, general anhedonia with a 10-lb weight gain. He initially attributed these symptoms to stress and change in job. Approximately
2 years after statin treatment initiation, he was diagnosed with acid reflux and began lansoprazole. The severity of his depression and perceived
irritability worsened, with manifestations including feelings of isolation, hopelessness, depression, and ‘‘passive-aggressive’’ anger with himself
and those around him. His wife noted a change in facial expression (always appearing to have an ‘‘angry face’’) as well as a change in personality,
and worried he was unhappy with the marriage
After several months of combined treatment, with intensified adverse mood/personality change, he discontinued the statin
Within 5 days after statin discontinuation, he had noted marked recovery from symptoms, including a return of his sense of humor and feelings of
happiness, increased productivity, and noted a better relationship with his wife. In addition, he observed a more relaxed facial expression had
replaced his angry facial appearance that had been characteristic while receiving statin treatment
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Table 3 continued
Case Case history
4 Case 4, a male in his 40s, full Professor at a major university, and internationally regarded scientist, with a family history of cardiovascular disease
was treated with atorvastatin 10 mg for hyperlipidemia (TC 210 mg/dL). Concomitant medications included flonase. He is described as a
previously strong, open, and spiritual person who was beloved by students and a treasured confidante for many of his friends and family. He was
reportedly a major figure in his field
Following initiation of statin use, he experienced extreme uncharacteristic changes in personality and behavior. Initially ascribed to stress at work,
these symptoms continued to progress, and by approximately 6 months on statins he and family members had become clearly aware of changes.
He developed insomnia (a reported statin adverse effect). Family members also began to notice signs of lethargy and deactivation (e.g., staring
into the ceiling for hours), as well as irritability and aggression (e.g., agitation and loss of temper at work): both of which were highly
uncharacteristic. Additionally, he experienced notable memory problems, including a loss of sense of direction for places he had been to
previously. He was prescribed zolpidem 5 mg for the insomnia, which he took only on rare occasions. 2–3 months before his death, he began
exercising and eating more fruit in an effort to combat his general feeling of malaise while receiving the statin treatment. He was found to have
contacted a statin adverse effect website. Other potential statin-related side effects he experienced that he reported to the website included
hearing problems, eczema, muscle pains, and temporary memory loss. It was later discovered that 2 months prior to his death he also began
logging on to a suicide website under an assumed name where users assisted one another in attempts, and had set the date and method for his own
suicide. Family members noted this as a very strange discovery, as deceptiveness was uncharacteristic of him; he had previously been known for
an open, honest, and candid personality. 1 month before his death, behavioral changes became increasingly evident, and family members
particularly noted his ‘‘disheveled appearance’’ contrasting with his normally well-groomed habits. Approximately 2 weeks prior to his death, he
had a cholesterol reading of 120 mg/dL. 1 week prior, he was found furtively moving helium tanks in the household, which he claimed were for a
family member’s birthday. 3 days before his suicide, he began exhibiting notable paranoia; manifestations included panic when his children were
not present in the same room and continual fear that someone may be after him and his family
Following approximately 1 year of lipid therapy and adverse personality change, he went to work, and in the evening called his wife to run errands
at the store stating he would be home afterwards. Later that evening he committed asphyxial suicide by inhalation of helium in conjunction with
the use of zolpidem and alprazolam. (Benzodiazepines are also linked to adverse behavioral sequelae. Here initiated for sleep problems arising
following statin use. Though he reportedly took these ‘‘rarely’’, a contribution by these agents cannot be excluded)
Factors meriting note: no history of alcohol abuse, and no familial history of psychiatric illness
5 Case 5 is a professionala male in his late 30s with an advanced degree who was receiving levothyroxine for hypothyroidism. He was placed on
fenofibrate, which was then successively combined with rosuvastatin or atorvastatin to treat hyperlipidemia, including elevated TRGs (TC
209 mg/dL, TRG 620 mg/dL, and HDL 23 mg/dL)
1 month into lipid treatment, he began to notice personality changes, felt ‘‘on edge’’, and exhibited increased temper directed particularly toward
his wife. Other manifestations included reading/interpreting facial expressions as more hostile [44], himself exhibiting a hostile facial expression,
increased temper on the road, and verbal fighting with his wife. Other statin side effects noted were fatigue and memory problems. His wife
reported he was easily provoked, became cynical, began having road rage (e.g., honking when others were not), had a ‘‘short fuse’’, instigated
fights for no reason, and was lethargic at work when he was previously driven to succeed. Relatives also noted his increased anger and irritability.
His wife sought solace outside the marriage, then separated and filed for divorce, citing the anger, irritability, and increased arguments
After 16 months of lipid treatment accompanied by adverse personality change, he discontinued lipid medications
By 1 week after drug discontinuation, he had already noted improvement in temper and increased patience, as well as increased energy, reduction
in sleeping hours required, and reduction in appetite (which had increased on statins). 3 weeks after discontinuation, he also noted he was able to
be more physically active, had increased sweating ability, modest weight loss, reduced anxiety/‘‘worry’’, and reduced irritability. When we
followed up with him longer term, he sounded markedly different relative to the first call. His personality and voice patterns were lively,
enthusiastic, and joyful with laughter, and was engaged and interested in ideas (vs. previously perceived as much more intense and introverted).
As his wife had commenced other involvements, divorce proceedings remained underway
6 Case 6 was a male in his late 40s with a long history of bipolar disorder who had responded remarkably well to lithium. His family describes him as
successful and brilliant; he was the president of an international organization and managed his own business. He was treated with cholestyramine
and niacin for familial hyperlipidemia and a family history of cardiovascular disease, without apparent psychiatric sequelae. Following years of
successful lithium therapy and psychiatric stability, he was switched to lovastatin
Shortly after he commenced statin treatment, his longstanding psychiatric stability was extinguished. He began experiencing major episodes of
mania and depression. Manifestations included inability to get out of bed and loss of interest in work. These episodes had a drastic impact on his
occupation; he gave up on his business and although highly qualified was unable to find another job because of his depression. He attempted to
combat his depression with exercise, drumming, writing, attending seminars, seeing doctors, and undergoing therapy. He began to lose interest in
activities he normally enjoyed, and the episodes also began straining his marriage of 10 years and his relationship with his children
Following 1 year of statin therapy with sustained psychiatric dyscontrol, he made his first suicide attempt. A little over 3.5 years after commencing
the statin, his TC was 133 mg/dL. At this time he began to undergo psychotherapy 6 days a week, and was unsuccessfully treated with a variety
of antidepressants, but continued lovastatin and lithium treatment throughout. Two more suicide attempts occurred during this period of time, and
approximately 6 months later he experienced a fatal stroke. Of note, a first-degree relative reported experiencing behavioral changes with statin
use
Factors meriting note: family history of psychiatric statin side effects, family and personal history of psychiatric disorders, no history of alcohol
abuse
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Table 3 continued
Case Case history
7 Case 7 was a male in his late teens who commenced atorvastatin 20 mg for familial hyperlipidemia. He had a family history of psychiatric illness
and adverse behavioral reaction to statins. His mother states that, prior to statin initiation, he was a ‘‘gracious, loving, and kind’’ person and good
student, beloved by his teachers
Within 2 weeks of statin initiation, he began experiencing nightmares with homicidal thoughts; manifestations included nightmares involving guns
and knives, which in one instance was violent enough to wake him and provoke him to jump out of a window. Normally a student who wanted to
excel, he began experiencing attention and concentration problems, which progressed to development of severe difficulty with reading within
months of starting the drug, which affected his school work. After 6 months receiving statin treatment, he was tested for and diagnosed with
severe attention deficit disorder, for which there had been no evidence prior to statin initiation. He was treated with psychostimulants, including
methylphenidate and amphetamines. Soon after he was diagnosed with depression and began seeing a therapist and commenced citalopram use.
He stopped the psychostimulants within weeks as he ‘‘did not like how he felt on it’’, and discontinued the antidepressants within 8–9 months.
Other manifestations included sleep walking, agitation, and anxiety with test taking
Following over 2 years of statin use and persistent behavioral/cognitive problems, he discontinued statin use, and family members noted rapid
marked improvement in personality and cognitive function, including resolution of nightmares, restoration of his prior happier disposition,
resumption of ability to concentrate and restoration of the ability to read. These improvements remained (stable and/or progressive) for the
6 weeks he remained off statin therapy
After 6 weeks off statins with sustained improvement, he resumed statin treatment, and within days the violent nightmares, difficulty with
concentration, and depression had reemerged. By 2 weeks after reintroduction of the statin (2.5 years after first commencing statins), he had
purchased a gun, and committed suicide with a self-inflicted gunshot wound
Factors meriting note: family history of statin psychiatric side effects, family history of psychiatric disorders, no history of alcohol abuse
8 Case 8 was a male in his 60s with a history of heart attack, triple bypass, and angioplasty. He had no psychiatric history, and family members
described him, pre-statin, as a strong-headed and lively personality, who was well known in his community for being social. He owned a small
business, was a member of a local sports team, and was active in local politics. He was placed on simvastatin 10 mg; concomitant medications
included torasemide, propranolol, and nitroglycerin
After commencing statins, he experienced new and marked changes in personality: his family declared he was ‘‘not himself’’. His wife noted
increased irritability as well as a short temper, and stated that their marriage of several years was becoming ‘‘difficult’’. His daughter also noted
that he gradually began to isolate himself and avoid social situations, including socializing with friends and going to family functions; this
became progressively worse during treatment. Family members stated he became increasingly overwhelmed by situations he would normally not,
and had also adopted a demeanor of hopelessness. A year and half after his statin initiation, he began to note joint and muscle problems
Approximately 2 years after commencing the statin, after some troubles with his business, he committed suicide by a self-inflicted gunshot wound.
Notably, two family members (his sister and his nephew) had also reported experiencing depression and mood changes in conjunction with statin
use
Factors meriting note: family history of statin psychiatric side effects, no history of alcohol abuse
9 Case 9 is a male professionala in his 60s who commenced simvastatin 20 mg (concomitant medications include valsartan and omeprazole) for a TC
of 253 mg/dL, LDL 169 mg/dL, HDL 48 mg/dL, and TRG 178 mg/dL
Following statin initiation, he began to note extreme irritability. Manifestations included a short temper, road rage, and snapping at his wife over
minor problems. His wife also noted his change in mood and mentioned he seemed exceedingly ‘‘grumpy’’. In addition, he noted he became more
emotional (e.g., would unexplainably tear up while reading a novel or watching a movie) and felt light-headed and ‘‘not right’’, both of which he
stated were unlike his usual personality. He continued statin treatment and his symptoms persisted for over a year and a half. During this time,
cholesterol levels were TC 175 mg/dL, LDL 92 mg/dL, HDL 49 mg/dL, and TRG 170 mg/dL. Other noted adverse effects included memory loss
(including diagnosed transient global amnesia), cognitive problems, and a dermatologic reaction. He sought to discontinue the statin, but the brief
effort was aborted when he was placed on atorvastatin 10 mg after a diagnosis of a carotid stenosis. The adverse personality changes persisted,
and were newly accompanied by muscle pain in the quadriceps
Following 8 months of treatment on atorvastatin and over 2 years on statins, with persistent adverse personality change, he discontinued treatment
due to the changes in personality and memory
By 1 week after discontinuation, he noted significantly reduced irritability and temper (and a ‘‘mellower’’ personality), as well as a resolution of his
skin rash (TC 225 mg/dL, LDL 143 mg/dL, HDL 53 mg/dL, and TRG 144 mg/dL). The improvement has been sustained on long-term follow-
up. Approximately 1 year after discontinuing the statin, he notes he remains a ‘‘much happier camper’’ off statins, much more ‘‘mellow’’ and less
prone to quick anger. He observes that during his half-hour commute to work he no longer expresses himself loudly at other drivers. Additionally,
his wife also commented he no longer is sharp towards her. He now seeks to manage his cholesterol through diet and exercise
Factors meriting note include glucose intolerance and significant environmental exposures when younger, no familial history of psychiatric illness
10 Case 10 is a male professionala in his late 30s with familial hyperlipidemia and no psychiatric history. His dose of atorvastatin was increased over a
short time from 10 to 20 and then 40 mg
Within weeks of the dose increase, he experienced new anxiety and externally directed violent ideation that was deeply disturbing. (At his
preference, additional details will not be given). These symptoms persisted. He communicated with our study group to inquire whether the statin
dose change could play a role. We felt the possibility of a statin connection could not be excluded, given the close temporal relation of dose
increase to symptom onset, on a backdrop of previously stable state with no prior suggestion of similar symptoms. He elected to do a trial off
statins
Following several months on the higher-dose statin, with deeply disturbing violent ideation sustained throughout these months, he discontinued
statin treatment
The violent ideation abated promptly and had resolved completely by 2 weeks off the statins. He has remained without hint of recurrence on long-
term follow-up (several years later)
Factors meriting note: family history of statin side effects
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no gauge of severity; and physical problems can them-
selves contribute to some level of psychic distress).
Some of our participants had underlying conditions
(such as a psychiatric disorder) that can themselves lead
to an adverse outcome; however, as above, the odds ratios
for risk of psychiatric events due to a drug can be mag-
nified in the presence of a psychiatric history [6]. Con-
sistent with this, most of the excess cases of violent death
arising in the active treatment, cholesterol-lowering arms
in a pre-statin-era analysis of randomized trials had other
risk factors for violent death [66]; since those risk factors
themselves were not shown to be increased in the active
treatment group, this underscores that individuals with
such issues may represent a vulnerable subgroup (as with
mefloquine). As a further analogy, an analysis of rhab-
domyolysis cases in the San Diego area showed that
typical instances involved the confluence of more than
one risk factor—consistent again with an increase in the
odds of an event ‘‘due to’’ each agent, in the presence of
the other [95]. In our cases, factors such as the temporal
relation to statin use, and concurrence of other statin-
compatible ADRs increases the prospects for causality
with statins.
Data rely on self-report. However, patient self-reports of
ADRs can be a valuable and reliable tool [96–100], and—if
heeded—may hasten recognition of important ADRs [101];
such benefits have led to standardized implementation of
patient reporting for EU-based pharmacovigilance data-
bases [102]. Self-selection of participants is inherent to
studies with volunteer patients; however, for studying those
with ADRs, whether or not they reflect typical effects,
observed effects are important.
Table 3 continued
Case Case history
11 Case 11 is a male in his 50s who began atorvastatin 20 mg for hyperlipidemia (concomitant medications include lisinopril and
hydrochlorothiazide). He then switched to simvastatin 20 mg
Approximately 2 weeks after the switch to simvastatin he noted no change; however, his wife cited notable fatigue and mood changes. In addition
to his inactivity, she stated he was extremely irritable and had extreme mood swings, describing him as ‘‘explosive’’. The two had arguments
almost every day and his wife commented the verbal exchanges would become aggressive. As he continued simvastatin use, she noted his
irritability progressively worsened
After the husband–wife pair discussed the issue with his general practitioner, following persistent problems while on simvastatin, he discontinued
his cholesterol drug use
2–3 weeks after drug discontinuation, his wife noted he was less fatigued and displayed a more calm and peaceful demeanor. He did not notice any
changes. In a 1-month follow-up, he noted he was slightly less fatigued, and his wife stated his mood had become noticeably more ‘‘mellow’’ and
patient, with fewer arguments and mood swings
He subsequently resumed statin use, with recurrence of reported marked increase in irritability cited by the wife (arising*1–2 months after statin
reintroduction), who stated these were sufficient to seriously threaten their marriage
12 Case 12 is a male in his mid-40s with a history of familial hypercholesterolemia and a family history of cardiovascular disease. He began lovastatin
treatment for elevated LDL levels. He reportedly had a very calm temperament prior to initiating statins
Immediately, 1 day after starting the statin, he developed markedly uncharacteristic severe irritability and aggression and cognitive dysfunction.
Manifestations included anger directed toward his wife and family members
Based on the notable changes in mood, 3 days later his wife suggested he discontinue the statins, and his aggression quickly resolved
3 years later, he began trials of the lowest dosages of each of several statins available to manage his cholesterol. Following each of atorvastatin,
simvastatin, and rosuvastatin, he developed similar changes in mood, including aggression, irritability, lack of patience, and violent ideation.
Manifestations included arguing and yelling directed at his wife, children, and clients at work, affecting his family and business. He noted
increased aggressive behavior while driving, and ‘‘unnerving’’ violent ideation towards others. Mood changes were virtually immediate with
initiating each statin: he stated his wife could determine whether he was on the statin based on his mood and behavior changes. In addition to his
mood changes, he also experienced mental confusion. He attempted to reduce the dosages of each statin to as low as 1 mg and change his diet,
but continued to experience side effects
He discontinued each statin for 2 weeks at a time, with his anger and irritability resolving virtually immediately, and returning when the statins
were resumed. He experienced the most prominent side effects with rosuvastatin, followed by the atorvastatin, and described both as ‘‘mind-
altering drugs’’
His final switch to pravastatin 40 mg resulted in no notable mood or behavior changes, and he successfully continued its use. However, 7 years
later, he discontinued its use due to shortness of breath and foot pain diagnosed as plantar fasciitis, which resolved following discontinuation
Several years later, he noted similar symptoms after ingesting bergamot, which inhibits HMG-CoA reductase and lowers cholesterol [45]
Information for cases 1, 4, 6, 7, and 8 (all of whom are deceased) was obtained via proxy surveys completed by close family members. ‘‘Factors meriting
note’’ designates considerations that relate to likelihood of adverse effect occurrence or protection (e.g., risk factors or their absence)
AE adverse event, ALT alanine aminotransferase, CAD coronary artery disease, GI gastrointestinal, HDL high-density lipoprotein cholesterol, HMG-CoA
3-hydroxy-3-methylglutaryl coenzyme A, LDL low-density lipoprotein cholesterol, SPECT single-photon emission computed tomography, TC total
cholesterol, TRG triglycerides
a Professional here refers to those with advanced degrees: MDs, PhDs, or JDs (except for deceased individuals, identifying information is kept general due
to the sensitive nature of the effects). A further (13th) case involving behavioral adverse effects is planned for inclusion in a separate case series on
physicians with statin adverse effects
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Conclusions
Though statins are widely tolerated, they may be among the
growing list of prescription agents that, in some participants,
may increase the risk of serious psychiatric events and/or
behavioral changes. In the cases cited here, these adverse
experiences posed risks to the safety of self and others—
sometimes, tragically, adversely affecting marriages and
careers, or culminating in death. The possibility of such
ADRs, even if rare, should be recognized by physicians who
prescribe cholesterol-lowering drugs, such that if personality
or behavior changes arise, the drug can be included in
considerations of etiology and treatment. This series extends
the modest literature on behavior and psychiatric changes
apparently associated with cholesterol-lowering treatment.
These findings further the evidence that cholesterol-lowering
drugs should be added to the list of agents that bear con-
sideration when new irritability, or aggressive or violent
behavioral changes arise.
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